Akari Therapeutics (AKTX) Return on Capital Employed (2015 - 2026)
Akari Therapeutics (AKTX) reported Return on Capital Employed of 107.4% for Q1 2026, up 31429.0% on a YoY basis from N/an in Q1 2025, and down 113.14% sequentially from 50.39% in Q4 2025.
Akari Therapeutics (AKTX) Return on Capital Employed (2015 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 5 years of Return on Capital Employed data on file, last reported at 107.4% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 31429.0% year-over-year to 107.4%; the trailing twelve-month figure through Mar 2026 stood at 107.4% (up 31429.0% YoY), and the FY2025 full-year result was 46.85%, up 23987.0% from the prior year.
- Return on Capital Employed fell to 107.4% in Q1 2026, from 50.39% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 659.1% in Q1 2024 to a low of 1904.88% in Q4 2024.
- A 3-year average of 194.45% and a median of 107.4% in 2026 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 185449 bps in 2025, while the deepest fall reached 108078 bps in 2025.
- Tracing AKTX's Return on Capital Employed over 3 years: stood at 1904.88% in 2024, then soared by 97 bps to 50.39% in 2025, then slumped by 113 bps to 107.4% in 2026.
- Business Quant data shows AKTX's Return on Capital Employed at 107.4% in Q1 2026, 50.39% in Q4 2025, and 386.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 20.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107.40% |
| Dec 31, 2025 | -50.39% |
| Sep 30, 2025 | -386.90% |
| Jun 30, 2025 | -359.67% |
| Mar 31, 2025 | -421.68% |
| Dec 31, 2024 | -1,904.88% |
| Sep 30, 2024 | 388.47% |
| Jun 30, 2024 | 433.26% |
| Mar 31, 2024 | 659.10% |
| Mar 31, 2016 | -66.01% |
| Dec 31, 2015 | -57.53% |
| Sep 30, 2015 | -842.18% |
| Jun 30, 2015 | -165.53% |
| Mar 31, 2015 | -180.18% |